[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 240, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1278804, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. JoAnne Micale Foody FACC, M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 856871, "exercisedValue": 0, "unexercisedValue": 3822}, {"maxAge": 1, "name": "Mr. Eric J. Warren R.Ph.", "age": 51, "title": "Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 718859, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 37, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 65, "title": "Chief Technical Operations Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 41, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 550350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.3, "open": 2.31, "dayLow": 2.275, "dayHigh": 2.6, "regularMarketPreviousClose": 2.3, "regularMarketOpen": 2.31, "regularMarketDayLow": 2.275, "regularMarketDayHigh": 2.6, "beta": 0.888, "forwardPE": -129.5, "volume": 10464186, "regularMarketVolume": 10464186, "averageVolume": 7243091, "averageVolume10days": 11592110, "averageDailyVolume10Day": 11592110, "bid": 2.56, "ask": 2.6, "bidSize": 1800, "askSize": 4000, "marketCap": 490701376, "fiftyTwoWeekLow": 0.7, "fiftyTwoWeekHigh": 3.4, "priceToSalesTrailing12Months": 2.1358988, "fiftyDayAverage": 2.28, "twoHundredDayAverage": 1.83445, "currency": "USD", "enterpriseValue": 945360000, "profitMargins": -0.37654, "floatShares": 173379088, "sharesOutstanding": 189460000, "sharesShort": 19867208, "sharesShortPriorMonth": 19922282, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.1058, "heldPercentInsiders": 0.0045, "heldPercentInstitutions": 0.65931, "shortRatio": 2.79, "shortPercentOfFloat": 0.106000006, "impliedSharesOutstanding": 189460000, "bookValue": -3.849, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -86507000, "trailingEps": -0.9, "forwardEps": -0.02, "pegRatio": -0.76, "enterpriseToRevenue": 4.115, "enterpriseToEbitda": -27.35, "52WeekChange": 0.57926834, "SandP52WeekChange": 0.26362717, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ESPR", "underlyingSymbol": "ESPR", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "firstTradeDateEpochUtc": 1372253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "00314c6d-38c1-3c8e-a318-bd51d9ba1c8c", "messageBoardId": "finmb_28236", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.59, "targetHighPrice": 16.0, "targetLowPrice": 2.9, "targetMeanPrice": 7.41, "targetMedianPrice": 8.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 82248000, "totalCashPerShare": 0.438, "ebitda": -34565000, "totalDebt": 540947008, "totalRevenue": 229740000, "revenuePerShare": 1.826, "revenueGrowth": 4.661, "grossMargins": 0.52199, "ebitdaMargins": -0.15045, "operatingMargins": 0.5247, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-17"}]